CoMentis Company
![](/storage/logos_100px/CoMentis.png)
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Technology:
Stem Cell
Industry:
Regenerative medicine
Headquarters:
United States
Founded Date:
2004
Employees Number:
51-100
Funding Status:
Late Stage Venture
Investors Number:
14
Total Funding:
$107.5M
Last Funding Type:
Series E
Register and Claim Ownership